BOLT.TA - BioLight Life Sciences Ltd.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
1,110.00
+3.00 (+0.27%)
As of 10:26AM IDT. Market open.
Stock chart is not supported by your current browser
Previous Close1,107.00
Open1,120.00
Bid1,119.00 x 70000
Ask1,143.00 x 74800
Day's Range1,110.00 - 1,150.00
52 Week Range1,110.00 - 1,683.11
Volume1,991
Avg. Volume1,886
Market Cap50.426M
Beta0.37
PE Ratio (TTM)N/A
EPS (TTM)-4.57
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00
  • BioLight Life Sciences Ltd. :BOLT-IL: Earnings Analysis: Q4, 2016 By the Numbers : November 13, 2017
    Capital Cube8 months ago

    BioLight Life Sciences Ltd. :BOLT-IL: Earnings Analysis: Q4, 2016 By the Numbers : November 13, 2017

    Categories: Yahoo FinanceGet free summary analysis BioLight Life Sciences Ltd. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of BioLight Life Sciences Ltd. – Teva Pharmaceutical Industries Limited (TEVA-IL) that have also reported for this period. Highlights Summary numbers: Revenues of ILS 0.34 million, Net Earnings ... Read more (Read more...)

  • PR Newswirelast year

    BioLight Reports Successful Results in Phase 1/2a Clinical Trial for Glaucoma Insert

    BioLight Life Sciences Ltd. (BOLT.TA) ("BioLight"), an emerging global ophthalmic company focused on the discovery, development and commercialization of ophthalmic products and product candidates, announced today successful results from its glaucoma insert VS101 ("Eye-D latanoprost insert") Phase 1/2a clinical trial, which demonstrated its ability to lower intraocular pressure ("IOP") for a 12-week period, with a favorable safety profile. The Eye-D latanoprost insert is designed to provide sustained IOP-lowering for patients who have difficulty taking their prescribed eye drops for the treatment of glaucoma on a continuous daily basis.

  • We're sorry this is all we were able to find about this topic.